Comprehensive genetic and functional analyses of Fc gamma receptors influence on response to rituximab therapy for autoimmunityResearch in context

Autor: James I. Robinson, Md Yuzaiful Md Yusof, Vinny Davies, Dawn Wild, Michael Morgan, John C. Taylor, Yasser El-Sherbiny, David L. Morris, Lu Liu, Andy C. Rawstron, Maya H. Buch, Darren Plant, Heather J. Cordell, John D. Isaacs, Ian N. Bruce, Paul Emery, Anne Barton, Timothy J. Vyse, Jennifer H. Barrett, Edward M. Vital, Ann W. Morgan

Publikováno v: EBioMedicine, Vol 86, Iss , Pp 104343- (2022)

Summary: Background: Rituximab is widely used to treat autoimmunity but clinical response varies. Efficacy is determined by the efficiency of B-cell depletion, which may depend on various Fc gamma receptor (FcγR)-dependent mechanisms. Study of FcγR

Externí odkaz: https://doaj.org/article/737647859b7c4fa4b27b129f6871d9c8

GA101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL (GALACTIC) trial: study protocol for a phase II/III randomised controlled trial

Autor: Jamie B. Oughton, Laura Collett, Dena R. Howard, Anna Hockaday, Talha Munir, Kathryn McMahon, Lucy McParland, Claire Dimbleby, David Phillips, Andy C. Rawstron, Peter Hillmen

Publikováno v: Trials, Vol 18, Iss 1, Pp 1-12 (2017)

Abstract Background Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia. Achieving minimal residual disease (MRD) negativity in CLL is an independent predictor of survival even with a variety of different treatment approaches and r

Externí odkaz: https://doaj.org/article/85a3ae6118144f27ac5415aae69c87c7

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations

Autor: Davide Rossi, Ritsuro Suzuki, Xavier Badoux, Eduardo Cervera Ceballos, Florence Cymbalista, Alexander Egle, Virginia Abello, Hoa T. T. Tran, Peter Hillmen, Stephen P. Mulligan, Jennifer R. Brown, William G. Wierda, Stephan Stilgenbauer, Yair Herishanu, Teoman Soysal, Andy C. Rawstron, Colin P. Diong, Carsten Utoft Niemann, Shang Ju Wu, Paolo Ghia, Carolyn Owen

Publikováno v: Wierda, W G, Rawstron, A, Cymbalista, F, Badoux, X, Rossi, D, Brown, J R, Egle, A, Abello, V, Cervera Ceballos, E, Herishanu, Y, Mulligan, S P, Niemann, C U, Diong, C P, Soysal, T, Suzuki, R, Tran, H T T, Wu, S J, Owen, C, Stilgenbauer, S, Ghia, P & Hillmen, P 2021, ' Measurable residual disease in chronic lymphocytic leukemia : expert review and consensus recommendations ', Leukemia, vol. 35, no. 11, pp. 3059-3072 . https://doi.org/10.1038/s41375-021-01241-1
Leukemia

Assessment of measurable residual disease (often referred to as “minimal residual disease”) has emerged as a highly sensitive indicator of disease burden during and at the end of treatment and has been correlated with time-to-event outcomes in ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774cd7230252f45f812f53d22e909b45
https://doi.org/10.1038/s41375-021-01241-1

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Autor: Talha Munir, Louise-Rae Cherrill, Nichola Webster, Surita Dalal, Rebecca H. Boucher, Chhaya Sankhalpara, Francesca Yates, Sonia Fox, Donald Macdonald, Christopher Fegan, Alison McCaig, Anna Schuh, Andrew Pettitt, John G. Gribben, Piers E.M. Patten, Stephen Devereux, Adrian Bloor, Christopher P Fox, Francesco Forconi, Andy C. Rawstron, Peter Hillmen

Publikováno v: Blood. 140:222-223

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::758153ca46224584b3308e192bd72d49
https://doi.org/10.1182/blood-2022-166700

P245 Identifying predictors of short-term response to rituximab in extra-glandular primary Sjogren’s Syndrome

Autor: Sophanit Pepple, Jack Arnold, Edward M Vital, Andy C Rawstron, Colin Pease, Shouvik Dass, Paul Emery, Md Yuzaiful, Md Yusof

Publikováno v: Rheumatology. 61

Background/Aims Randomised controlled trials (RCTs) of rituximab (RTX) in primary Sjogren’s syndrome (pSS) have failed to alleviate glandular symptoms and fatigue. The question remains as to whether B-cell depleting therapies have a place for the t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6524195ebabb14e203dd134f30239369
https://doi.org/10.1093/rheumatology/keac133.244